NZ514478A - A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate - Google Patents

A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate

Info

Publication number
NZ514478A
NZ514478A NZ514478A NZ51447800A NZ514478A NZ 514478 A NZ514478 A NZ 514478A NZ 514478 A NZ514478 A NZ 514478A NZ 51447800 A NZ51447800 A NZ 51447800A NZ 514478 A NZ514478 A NZ 514478A
Authority
NZ
New Zealand
Prior art keywords
bisphosphonate
pharmaceutical formulation
additive agent
agent providing
enhanced absorption
Prior art date
Application number
NZ514478A
Inventor
Lennart Lindfors
Jan-Erik Lofroth
Sven Sjogren
Anna-Lena Ungell
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ514478A publication Critical patent/NZ514478A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides pharmaceutical formulations comprising at least one bisphosphonate and an additive consisting of one or more absorption enhancing agents. The said pharmaceutical formulations are useful for the inhibition of bone resorption and for the treatment and prevention of osteoporosis.
NZ514478A 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate NZ514478A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901272A SE9901272D0 (en) 1999-04-09 1999-04-09 New improved formulation
PCT/SE2000/000664 WO2000061111A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate

Publications (1)

Publication Number Publication Date
NZ514478A true NZ514478A (en) 2004-01-30

Family

ID=20415159

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514478A NZ514478A (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate

Country Status (11)

Country Link
EP (1) EP1171097A1 (en)
JP (1) JP2002541185A (en)
KR (1) KR20010104389A (en)
AU (1) AU4161900A (en)
CA (1) CA2364659A1 (en)
IL (1) IL145506A0 (en)
NO (1) NO20014895L (en)
NZ (1) NZ514478A (en)
SE (1) SE9901272D0 (en)
WO (1) WO2000061111A1 (en)
ZA (1) ZA200108260B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
AU2001251432A1 (en) 2000-04-07 2001-10-23 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use ofthe compositions as bisphosphate delivery systems with reduced gi toxicity
WO2001085217A1 (en) * 2000-05-05 2001-11-15 F. Hoffmann-La Roche Ag Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts
JP4354698B2 (en) 2001-03-01 2009-10-28 エミスフェアー・テクノロジーズ・インク Bisphosphonate delivery composition
AU2002330692A1 (en) 2001-07-02 2003-01-21 Elan Corporation, Plc. Delivery of a bioactive material
ES2532393T3 (en) 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Bisphosphonic acids for treatment and prevention of osteoporosis
NZ536273A (en) 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
ATE402942T1 (en) * 2003-01-17 2008-08-15 Teva Pharma METHOD FOR REDUCING IRON CONTENT IN RISEDRONATE SODIUM
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2004110458A1 (en) * 2003-05-16 2004-12-23 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
ATE475412T1 (en) * 2004-05-24 2010-08-15 Warner Chilcott Co Llc ENTERIC SOLID ORAL DOSAGE FORM OF A BISPHOSPHONATE WITH A CHELATE
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
KR100815040B1 (en) * 2005-01-31 2008-03-18 주식회사종근당 Pharmaceutical compositions containing bisphosphonate for improving oral absorption
NO20053519L (en) * 2005-07-18 2007-01-19 Thia Medica As Use of compounds comprising fatty acids
EP2007397B1 (en) 2006-04-07 2013-07-24 Merrion Research III Limited Solid oral dosage form containing an enhancer
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
TW200950799A (en) 2008-05-07 2009-12-16 Merrion Res Iii Ltd Compositions of GnRH related compounds and processes of preparation
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
KR101631243B1 (en) * 2009-05-13 2016-06-17 신일제약주식회사 Method for preparing novel alendronate emulsion dried product and pharmaceutical composition containing the same
EP3295935B1 (en) 2009-07-31 2020-07-22 Grünenthal GmbH Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
FR2954320B1 (en) 2009-12-17 2012-06-15 Cll Pharma SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
CA2819234A1 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
KR20120105738A (en) * 2011-03-16 2012-09-26 현대약품 주식회사 An enteric-coated oral formulation
JP5874545B2 (en) * 2011-06-20 2016-03-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration
WO2016120378A1 (en) 2015-01-29 2016-08-04 Novo Nordisk A/S Tablets comprising glp-1 agonist and enteric coating
US20180161401A1 (en) * 2015-07-06 2018-06-14 Zheng Xin Dong Novel Formulations of PTHrP Analogue
EP3455229B1 (en) 2016-05-13 2021-03-24 Thar Pharma LLC Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN112972400A (en) * 2021-03-09 2021-06-18 华侨大学 Rapidly disintegrable minodronic acid granules and preparation method thereof
KR20240013402A (en) * 2022-07-22 2024-01-30 주식회사 아이큐어비앤피 Oral pharmaceutical composition comprising teriparatide for preventing or treating osteoporosis and method for preparing the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
EP0550385A1 (en) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers
TW237386B (en) * 1992-04-15 1995-01-01 Ciba Geigy
SE501389C2 (en) * 1992-04-24 1995-01-30 Leiras Oy Pharmaceutical preparation and process for its preparation
ES2065313T5 (en) * 1993-05-15 2004-01-01 Roche Diagnostics Gmbh TABLET WITH IMPROVED BIODISPONIBILITY CONTAINING DICHLOROMETILENDIFOSFONICO ACID AS ACTIVE SUBSTANCE.
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
FI109088B (en) * 1997-09-19 2002-05-31 Leiras Oy Tablet and process for its preparation
SE9703691D0 (en) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
NO20014895L (en) 2001-12-10
NO20014895D0 (en) 2001-10-08
ZA200108260B (en) 2003-03-26
SE9901272D0 (en) 1999-04-09
KR20010104389A (en) 2001-11-24
EP1171097A1 (en) 2002-01-16
IL145506A0 (en) 2002-06-30
CA2364659A1 (en) 2000-10-19
AU4161900A (en) 2000-11-14
WO2000061111A1 (en) 2000-10-19
JP2002541185A (en) 2002-12-03

Similar Documents

Publication Publication Date Title
NZ514478A (en) A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
EP1310259A3 (en) Formulation comprising a biphosphonate and an absorption enhancing agent for the treatment of osteoporosis
SI1663185T1 (en) Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
TR200101103T2 (en) Controlled release pharmaceutical formulations containing CGMP PDE-Inhibitor
NZ294933A (en) Thienopyridine or thienopyrimidine derivatives, pharmaceutical compositions and use as anti-inflammatory agents
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
SI1880744T1 (en) Bisphosphonic acids for the treatment and prevention of osteoporosis
MY118151A (en) Pharmaceutical formulations containing voriconazole.
DE60038038D1 (en) Phosphonatverbindungen
ATE232874T1 (en) PROSTAGLANDIN CONJUGATES FOR THE TREATMENT OF BONE DISEASES
HUP0004271A2 (en) Compositions comprising amylin or amylin agonist for treating obesity
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
AU6257798A (en) Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
HU9501121D0 (en) Pharmaceutical composition for treating osteoporosis
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
GB9804886D0 (en) Therapeutic combination
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
ZA97252B (en) Compositions for the prevention and treatment of osteoporosis.
AP2001002369A0 (en) Pharmaceutical complex.
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
EP1147773A4 (en) Medicinal compositions for treating osseous lesion in multiple myeloma
AU4546900A (en) Estrogen receptors and bone
MXPA03006468A (en) Compositions for prevention or treatment of hepatopathy.

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed